Santosh Saraf is an Oncology physician affiliated with University of Illinois Chicago. OpenAlex indexes 310 publications with 3,342 citations (h-index 28).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1740 W Taylor St
Dept 3462
Chicago, IL 606127232
Telephone
312-704-2885Registry record last updated 17 Jun 2015.
Industry payments
11 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Agios Pharmaceuticals, Inc.Program year202513 payments$11,637openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year202511 payments$11,075openpaymentsdata.cms.gov ↗
- Novo Nordisk IncProgram year20254 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
41.7%Opioid Agonist39.1%Morphine Sulfate26%Morphine Sulfate Er26%Hydromorphone Hcl23%Methadone Hcl11%Oxycodone Hcl7%Oxycontin7%Part D<11 patientsgamma-Aminobutyric Acid A Receptor Positive Modulator2.5%Zolpidem Tartrate100%Part D<11 patientsRespiratory
22.7%Opioid Agonist22.7%Hydrocodone-Acetaminophen100%Part D≥17 patientsBlood & clotting
10.6%Factor Xa inhibitor10.6%Eliquis61%Xarelto39%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
5 NIH research awards on record, funded 2015–2026 per NIH RePORTER. The latest:
- Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using SGLT2 Inhibitors
University of Illinois at Chicago
FY2026$741,340R01HL180499 - Mentoring & Patient-Oriented Research in Sickle Cell-Related Kidney Disease
University of Illinois at Chicago
FY2026$137,219K24HL177273 - Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using SGLT2 Inhibitors
University of Illinois at Chicago
FY2025$755,853R01HL180499
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
Similar KOLs
Other experts from the same institution or the same specialty.
Jerry Krishnan, MD
University of Illinois Chicago
Victor Gordeuk, MD
University of Illinois Chicago
Richard Penn, MD
University of Illinois Chicago
William Mieler, MD
University of Illinois Chicago
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”